Y-mAbs Therapeutics
New York
About Y-mAbs Therapeutics
YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients through immunotherapies. YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies. To further improve its bispecific antibodies, the company collaborates on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. YmAbs' treatments claims to potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA approval.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $50K – $100K
- Total funding: $338.8M
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2021)
- Ticker: nasdaq:YMAB
- Website: ymabs.com
- Phone: 1 212 847 9841
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/y-mabs-therapeutics-152927 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.